drugset / Trial / NCT00883090

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

NCT00883090 ↗

Phase 2 Completed 15 enrolled CSL Behring
NaSingle-groupOpen-label

Summary

Congenital deficiency of Factor XIII is an extremely rare hereditary disorder associated with potentially life-threatening bleeding. This study will evaluate the safety and recommended (best) amount or level of Factor XIII in a patient's blood. Factor XIII Concentrate (Human) is given to people whose blood is lacking Factor XIII. Factor XIII Concentrate (Human) works by assisting your blood in the usual clotting process, thereby preventing bleeding.

Timeline

Start
2009-05
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject FXIII Concentrate (Human) Protein / enzyme biologic 40 iu/kg Intravenous